Contact Us
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
At the BAD 2026 meeting, new analyses from BADBIR highlighted the value of real-world evidence in answering clinically important questions in psoriasis care. The data explored serious infection risk across systemic treatments, the potential benefits of using biologics earlier in the treatment pathway, and risk factors for incident and recurrent erythrodermic psoriasis. Together, these findings demonstrate how registry data can complement clinical trial evidence by providing insights from routine clinical practice and helping to inform more personalized treatment decisions.
touchDERMATOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
